Daily meet celebrity with new activity
Novartis mission
Novartis
Novartis CEO discusses how AI will impact drug development
Novartis CEO Vas Narasimhan on the latest research on a breast cancer drug
Novartis – Who We Are
Novartis as a focused innovative medicines company
25 Years of Novartis – Continuing our innovation journey
CEO of Swiss drugmaker Novartis outlines some major industry trends for 2024
Novartis transformation into a pure-play Innovative Medicines company
Novartis Raises Outlook After Sandoz Generics Spinoff
Research and Development: It’s our heartbeat.
Novartis CEO on Acquisitions, AI, Weight-Loss Drugs
Novartis areas of focus
Novartis CEO Vas Narasimhan on The David Rubenstein Show
Novartis Life
Meet the Novartis Prague team...
Novartis ‘focusing on high-end, innovative medicines,’ CEO says
Novartis Oncology - BOLD Science. Transforming Lives. Striving For Cures.
Novartis CEO on new cancer therapy programs
Novartis Can Meet Growing Demand for Gene Therapy: CEO
Imagine what you could do at Novartis
Novartis Cancer Drug Is Approved With $475,000 Price Tag
Manufacturing CAR-T Cell Therapies: The Novartis Approach
FDA approves Novartis gene therapy for rare genetic disorder
Novartis CEO: Expect continued growth in 2023
Reimagine what you could do at Novartis
The future of Novartis
Novartis has halted distribution of generic Zantac. Here's what you need to know.
How does Novartis create value for stakeholders and society?
Long Live Life: Connecting with the Novartis Mission
Reimagining Medicine with Data & Digital | Novartis CEO at #VivaTech19
Novartis CEO: Company set to become a pure play, innovative medicine business after Sandoz spin off
Novartis Research & Development
How are core Therapeutic Areas central to Novartis strategy?
The Evolution of Medicine
Novartis Financial Results Q1 2021
Harnessing the Science of Immuno-oncology at Novartis
Our Common Portrait. Associates of Novartis Global Service Center in Prague.
Strategy to become the most valued and trusted medicines company
Watch CNBC's full interview with Novartis CEO Vas Narasimhan
Novartis in 360 Ɩ See how robots aid drug discovery
Flexibility at Novartis: Shamsah Kazani
BUSINESS BULLETIN - India denies Novartis patent protection on cancer drug
Novartis 2022 Key Statistics
New frontiers of medicine – Cell and Gene Therapies
Vas explains Radioligand Therapy (RLT)
Novartis Targets Cancer Genomics for Precision Medicine
See how we’re reimagining medicine at Novartis
Novartis CEO Vas Narasimhan: Our medicines are starting to take market share and deliver on promises
Novartis in 360 Ɩ Tour our Compound Library